Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants

Exclusion Criteria

• •Allergic constitution.
• •Within 72 hours of the start of study treatment, the use of antihistamines or use of topical drugs at the application site.
• •Hair removing interventions including laser treatment, shaving and waxing in the target area within 1 week before Screening.
• •Hypertrichosis on the back; no tattoos that cover greater than 30% of the back surface area.
• •Presence of an inflammatory dermatosis (including, but not limited to, atopic dermatitis, eczema, psoriasis, extensive acne), and/or suntan/burn that could interfere with the test field evaluation.
• •Non-inflammatory skin lesions and changes (including, but not limited to, hyperpigmentation, multiple naevi, tattoos, blemishes, birthmarks, abrasions, ulcers, eschar, and/or scabs) present in the target area on the back that could interfere with the test field evaluation.
• •Any history of or presence of in situ melanoma and non-melanoma skin cancer within the last 3 years.
• •Any other skin disease or other visible skin condition noted on physical examination which in the Investigator's opinion might interfere with the evaluation of the test field reaction.